NCT01602224 · REGISTRY CONDITION SEARCH

A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2019-10-08

The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doctors will collect information about the effectiveness and side effects of this therapy.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression Free Survival (PFS)

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Time to First Skeletal-Related Event (SRE)

→

outcome · POSTED

Number of Participants With >30% Reduction in Brief Pain Inventory (BPI) - Worst Pain Score

→

outcome · POSTED

Time to Progression (TTP)

→

outcome · POSTED

Duration of Response (DoR)

→

outcome · POSTED

Time to Next Treatment (TNT)

→

outcome · POSTED

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tabalumab

→

outcome · POSTED

PK: Time to Maximum Plasma Concentration (Tmax) of Tabalumab

→

outcome · POSTED

PK: Area Under the Curve Over the Dosing Interval (AUC-T) for Tabalumab

→

outcome · POSTED

Number of Participants Developing Anti-tabalumab Antibodies

→

outcome · POSTED

Participants With Best Overall Response (BOR) in Each Category

→

outcome · POSTED

Number of Participants With a Given Best Objective Myeloma Response (Quality of Response [QoR])

→

outcome · POSTED

Overall Response Rate (ORR)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Have symptomatic and/or progressive MM that was previously treated with at least 1 and no more than 3 prior lines of therapy * Have measurable disease * Have given written informed consent prior to any study-specific procedures * Have adequate organ function * Treatment with prior autologous transplant is permitted Exclusion Criteria: * Are enrolled in or discontinued from a clinical trial of any drug or device within 21 days prior to the first dose of assigned study treatment * Have had less than a minimal response or have had progressive disease within 60 days of most recent therapy with a proteasome inhibitor * Plan to proceed to autologous transplant for consolidation after participation in this trial * Have an active infection or ongoing treatment for systemic infection ("ongoing treatment" does not include prophylactic anti-infectives),, chest x-ray suggestive of tuberculosis, or history/risk of chronic/latent infection that may reactivate in the presence of study therapy * Have any of the following: * positive test results for human immunodeficiency virus (HIV) * positive test for hepatitis B, defined as positive for hepatitis B surface antigen (HBsAg+), OR positive for anti-hepatitis B core antibody AND positive for hepatitis B deoxyribonucleic acid (HBV DNA), OR positive for anti-hepatitis B surface antibody (HBsAb+) AND positive for hepatitis B deoxyribonucleic acid (HBV DNA) * positive test results for hepatitis C virus (HCV), defined as positive for hepatitis C antibody (HepCAb) AND confirmed positive via the hepatitis C recombinant immunoblot assay * Have had significant allergy to human/humanized monoclonal antibodies that, in the opinion of the investigator, poses an unacceptable risk to the participants * Have known hypersensitivity or contraindication to any of the study therapies or excipients * Prior allogeneic hematopoietic stem cell transplant * Prior therapy with experimental agents targeting B-cell activating factor (BAFF), including LY2127399 * Have corrected QT (QTc) interval \>500 millisecond (msec) on baseline 12-lead electrocardiogram (ECG) * Have Waldenstrom's macroglobulinemia * History of malignancy with adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer, are eligible regardless of the time of diagnosis/treatment
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles. Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles. Bortezomib 1.3 milligram per square meter (mg/m\^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for a minimum 8 cycles. All treatment may continue past 8 cycles.
intervention Names
Drug: Dexamethasone
Drug: Bortezomib
Biological: Tabalumab
label
100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)
type
EXPERIMENTAL
description
Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles. Dexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles. Bortezomib 1.3 mg/m\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles. All treatment may continue past 8 cycles.
intervention Names
Drug: Dexamethasone
Drug: Bortezomib
Biological: Tabalumab
label
300 mg Tabalumab+Dexamethasone+Bortezomib
type
EXPERIMENTAL
description
Placebo administered once IV on Day 1 every 21 days for 8 cycles. Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles. Bortezomib 1.3 mg/m\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles. All treatment may continue past 8 cycles.
intervention Names
Drug: Placebo
Drug: Dexamethasone
Drug: Bortezomib
label
Placebo Comparator: Placebo + Dexamethasone + Bortezomib
type
PLACEBO_COMPARATOR

interventions

arm Group Labels
Placebo Comparator: Placebo + Dexamethasone + Bortezomib
description
Administered IV
name
Placebo
type
DRUG
arm Group Labels
100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)
300 mg Tabalumab+Dexamethasone+Bortezomib
Placebo Comparator: Placebo + Dexamethasone + Bortezomib
description
Administered orally
name
Dexamethasone
type
DRUG
arm Group Labels
100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)
300 mg Tabalumab+Dexamethasone+Bortezomib
Placebo Comparator: Placebo + Dexamethasone + Bortezomib
description
Administered SQ
name
Bortezomib
type
DRUG
arm Group Labels
100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)
300 mg Tabalumab+Dexamethasone+Bortezomib
description
Administered IV
name
Tabalumab
other Names
LY2127399
type
BIOLOGICAL

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: TRIPLE
who Masked: PARTICIPANT
CARE_PROVIDER
INVESTIGATOR

primary Purpose

TREATMENT

Enrollment

count: 220
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
PFS is defined as the time from date of first dose to the first observation of disease progression or death due to any cause. If a participant does not have a complete baseline disease assessment, then the PFS time is censored at the enrollment date, regardless of whether or not objectively determined disease progression (Increase of \> 25% from lowest response in serum M component, urine M component, bone marrow plasma cell percentage, development of bone lesions) or death has been observed for the participant. If a participant is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time is censored at the last complete objective progression-free disease assessment date.
measure
Progression Free Survival (PFS)
time Frame
Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months)

secondary Outcomes

description
Overall survival is the duration from enrollment to death from any cause. For participants who were alive, overall survival was censored at the last contact.
measure
Overall Survival
time Frame
Baseline to Death From Any Cause (assessed up to 19 months)
description
Time to first SRE is defined as time from randomization to any one of the following related to multiple myeloma: New Pathological Fracture, Spinal Cord Compression, Surgery to the Bone, Radiation to the Bone collected until participant death, study closure or lost to follow up. Participants not known to have had an SRE at the time of the analysis were censored at the date of their last complete documented assessment for SRE.
measure
Time to First Skeletal-Related Event (SRE)
time Frame
Baseline to Date of First Skeletal Related Event (assessed up to 19 months)
description
BPI is assessed by 7 questions rated "0" for "no pain" and higher numbers indicated more pain.
measure
Number of Participants With >30% Reduction in Brief Pain Inventory (BPI) - Worst Pain Score
time Frame
Baseline through End of Treatment (19 months)
description
Time to progression is defined as the time from the date of randomization to the date of first observed objective progression or death due to study disease. Time to progression will be censored as for PFS for those participants not known to have progressed or that died from other causes.
measure
Time to Progression (TTP)
time Frame
Baseline to Objective Disease Progression or Death (assessed up to 9 months)
description
DOR is measured by the International Myeloma Working Group Uniform Response Criteria: from the date of first evidence of a confirmed response to the date of objective progression or the date of death due to any cause, whichever is earlier. If a responder is not known to have died or have objective progression as of the data inclusion cutoff date, the DOR time will be censored at the last complete objective progression-free disease assessment date. Progressive disease is an increase of 25% from baseline in Serum M, Urine M, bone marrow plasma cell increase of 10 %, development of new bone lesions, development of new soft tissue plasmacytomas or bone lesions, hypercalcemia \>11.5 milligrams per deciliter, decrease in hemoglobin of 2 grams per deciliter, rise in serum creatinine by 2 mg/deciliter.
measure
Duration of Response (DoR)
time Frame
Time from Response to Objective Disease Progression (assessed up to 38 months)
description
TNT is defined as the time from the date of randomization to the date of initiation of the first poststudy treatment course of anticancer therapy or death from any cause. Time to next treatment will be censored at the date of the last visit for participant who did not initiate additional anticancer therapy.
measure
Time to Next Treatment (TNT)
time Frame
Baseline to Initiation of New Cancer Treatment or Death From Any Cause (18 Months)
description
Maximum Concentration (Cmax) of Tabalumab.
measure
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tabalumab
time Frame
Cycle (C)1 Day (D)1: Predose, 3O minutes, 2 hours Postdose; C1 D4, 8, 11: Predose, (D11 only, 30 minutes Postdose); C2 and C6-C10 D1: Predose and immediately Postdose; C2 D 4, 8, 11: Anytime
measure
PK: Time to Maximum Plasma Concentration (Tmax) of Tabalumab
time Frame
C1 D1: Predose, 3O minutes, 2 hours Postdose; C1 D4, 8, 11: Predose, (D11 only, 30 minutes Postdose); C2 and C6-C10 D1: Predose and immediately Postdose; C2 D 4, 8, 11: Anytime
measure
PK: Area Under the Curve Over the Dosing Interval (AUC-T) for Tabalumab
time Frame
C1 D1: Predose, 3O minutes, 2 hours Postdose; C1 D4, 8, 11: Predose, (D11 only, 30 minutes Postdose); C2 and C6-C10 D1: Predose and immediately Postdose; C2 D 4, 8, 11: Anytime
measure
Number of Participants Developing Anti-tabalumab Antibodies
time Frame
Baseline through Cycle 8
description
Stringent Complete Response-Complete Response and normal free light chain ration and no clonal cells in bone marrow Complete Response- no monoclonal protein (mp) in blood, no serum or urine mp, less than 5% plasma cells in bone marrow Very Good Partial Response-more than 90% decrease in mp and urine protein Partial Response- over 50% decrease in serum mp Stable Disease- less than 25 percent decrease of monoclonal protein Progressive Disease- 25% increase compared to lowest value of serum mp, urine mp, no measurable mp
measure
Participants With Best Overall Response (BOR) in Each Category
time Frame
Baseline to Objective Disease Progression or Initiation of New Cancer Treatment (28 Months)
description
Response categories in order of decreasing quality are: Stringent Complete Response(sCR),Complete Response(CR), Very Good Partial Response(VGPR),Partial Response(PR),Minimal Response(MR),Stable Disease(SD), or Progressive Disease(PD), according to the International Uniform Response Criteria for Multiple Myeloma.SCR:normal free light chain ration and no clonal cells in bone marrow;CR-no monoclonal protein(mp) in blood, no serum/urine,\<5% plasma cells in bone marrow; VGPR-more than 90% decrease in mp and urine protein; PR-\>50% decrease in serum MP;SD-\<25% decrease in mp; PD-25% increase compared to lowest value of serum mp, urine mp and no measurable mp.
measure
Number of Participants With a Given Best Objective Myeloma Response (Quality of Response [QoR])
time Frame
Baseline to Objective Disease Progression or Initiation of New Cancer Treatment (up to 28 Months)

Full study description

brief Summary: The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doctors will collect information about the effectiveness and side effects of this therapy.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-b5a8cfb2e6d739ce64b7
requested nct id
NCT01602224
primary nct id
NCT01602224
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
c3e136411519591780699d958049d827abd3d6dc35be0e87accf70c3a58c5434
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-b5a8cfb2e6d739ce64b7
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01602224
occurrences
context exact
NCT01602224
end
11
exact text
NCT01602224
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/242/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
cf511d39d760db7ba1638b1a575195e2af34288b68bd48ab1f65594c4dc6ebd7
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice